Bosutinib Efficacy, Safety, Tolerability (BEST) Study in Elderly Chronic Myeloid Leukemia Patients Failing Front-line Treatment With Other Tyrosine Kinase Inhibitors
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2016
At a glance
- Drugs Bosutinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms BEST
- 07 Jun 2017 Biomarkers information updated
- 21 Nov 2016 Planned End Date changed from 1 Sep 2021 to 1 Nov 2021.
- 21 Nov 2016 Planned primary completion date changed from 1 Sep 2019 to 1 Nov 2019.